Evolving Advances in the Applications of Carbon Nanotubes (CNTs) for Management of Rheumatoid Arthritis (RA).

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2024-03-18 DOI:10.2174/0122117385293018240312050646

Sarika J Patil, Vandana M Thorat, Akshada A Koparde, Rohit R Bhosale, Dhanashri D Chavan, Devkumar D Tiwari

{"title":"Evolving Advances in the Applications of Carbon Nanotubes (CNTs) for Management of Rheumatoid Arthritis (RA).","authors":"Sarika J Patil, Vandana M Thorat, Akshada A Koparde, Rohit R Bhosale, Dhanashri D Chavan, Devkumar D Tiwari","doi":"10.2174/0122117385293018240312050646","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic condition causing joint pain and inflammation that has now spurred the interest in nanotechnology-based drug delivery for more effective treatment, and in this regard, carbon nanotubes (CNTs) are being explored for their potential to deliver the drugs steadily to manage the RA. Many investigators have been investigating both single-walled carbon nanotubes (SWCNT) as well as multi-walled carbon nanotubes (MWCNT) for managing arthritis via targeted drug delivery. Moreover, functionalized CNTs show promise in delivering the drugs precisely and in a controlled manner, thereby minimizing toxicity. However, research on applications of CNTs as drug carriers for RA remains limited, thus necessitating further exploration to address the various challenges. In this present piece of writing, challenges in RA treatment and the advances in applications of CNTs for RA management are reported, consequently reflecting the CNTs as advanced drug delivery vehicles for arthritis treatment.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385293018240312050646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Rheumatoid arthritis (RA) is a chronic condition causing joint pain and inflammation that has now spurred the interest in nanotechnology-based drug delivery for more effective treatment, and in this regard, carbon nanotubes (CNTs) are being explored for their potential to deliver the drugs steadily to manage the RA. Many investigators have been investigating both single-walled carbon nanotubes (SWCNT) as well as multi-walled carbon nanotubes (MWCNT) for managing arthritis via targeted drug delivery. Moreover, functionalized CNTs show promise in delivering the drugs precisely and in a controlled manner, thereby minimizing toxicity. However, research on applications of CNTs as drug carriers for RA remains limited, thus necessitating further exploration to address the various challenges. In this present piece of writing, challenges in RA treatment and the advances in applications of CNTs for RA management are reported, consequently reflecting the CNTs as advanced drug delivery vehicles for arthritis treatment.

查看原文本刊更多论文

碳纳米管 (CNT) 在治疗类风湿性关节炎 (RA) 方面的应用进展。

类风湿性关节炎（RA）是一种引起关节疼痛和炎症的慢性疾病，目前已激发了人们对基于纳米技术的药物输送以实现更有效治疗的兴趣，在这方面，人们正在探索碳纳米管（CNT）稳定输送药物以控制 RA 的潜力。许多研究人员一直在研究单壁碳纳米管（SWCNT）和多壁碳纳米管（MWCNT），以通过靶向给药治疗关节炎。此外，功能化碳纳米管有望以可控方式精确递送药物，从而将毒性降至最低。然而，将 CNTs 作为药物载体用于治疗 RA 的研究仍然有限，因此有必要进一步探索，以应对各种挑战。本文报告了RA治疗面临的挑战以及应用碳纳米管治疗RA的进展，从而反映了碳纳米管作为先进药物载体在关节炎治疗中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.